Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor
- 1.5k Downloads
KeywordsVemurafenib Craniopharyngioma Prolactinoma BRAF Inhibitor BRAF V600E Mutation
The BRAF V600E mutation has recently been identified in a high percentage of papillary craniopharyngiomas [1, 2]. The V600E mutation constitutively activates the MEK-ERK pathway, and the mutation-specific BRAF inhibitor vemurafenib, which targets mutated BRAF, is effective in malignant melanoma . The use of vemurafenib in malignancy now includes hairy cell leukaemia which frequently carries the same mutation, thereby demonstrating that the agent targets the pathway rather than the specific tumor type . Papillary craniopharyngiomas are histologically benign but cause substantial morbidity due to visual loss, pituitary dysfunction, diabetes insipidus and hypothalamic disturbance. We report the first successful use of the BRAF inhibitor vemurafenib in a patient with progressive visual failure due to a recurrent papillary craniopharyngioma, thereby supporting the evidence that the BRAF V600E mutation is pathological in this condition.
The pretreatment MRI (Fig. 1c) showed an invasive sellar and suprasellar mass with perifocal edema (Fig. 1d). After 2 weeks on vemurafenib her vision stabilized and MRI showed a marked reduction in the size of the tumor with resolution of the surrounding edema (Fig. 1e, f). Three months after starting treatment there was near-complete resolution of the craniopharyngioma (Fig. 1g). Associated with tumor size reduction, she developed a CSF leak, pneumocephalus and meningitis, necessitating antimicrobial therapy and surgical repair. This is a recognised complication rarely observed when a prolactinoma shrinks with dopamine agonist therapy . Her vision improved and stabilized (RE NPL; LE 6/24) but she suffered frontal lobe volume loss with reduced cognitive status. Treatment was interrupted after 3 months but the tumor recurred within 6 weeks (not shown) and she restarted therapy with vemurafenib. Her tumor exhibited a further response and growth was stabilised until 7 months after treatment initiation when progressive regrowth was observed.
The discovery of the activating BRAF mutation in melanoma and the development of molecular targeted therapy represented a major advance in the management of melanoma. Our case now extends the potential use of vemurafenib to a different indication. Craniopharyngioma is a benign non-metastatic tumor with a low proliferation rate that grows slowly but inexorably and invades surrounding tissues. Treatment mainstays include either trans-sphenoidal or trans-cranial surgery, with external beam radiotherapy. This tumor frequently arises during childhood and the use of radiotherapy has to be balanced with long term sequelae of therapy. Furthermore, some patients require repeated surgeries to achieve tumor control and patients with craniopharyngioma sustain severe morbidity both as a result of the tumor and the treatments. There are no recognised targeted or cytotoxic treatments available.
In this case, proven to have a somatic BRAF V600E mutation, the tumor responded promptly and progressively to monotherapy with vemurafenib. It is noteworthy that regrowth was rapid with interruption of treatment which should be considered in future cases. The molecular targeted use of the BRAF inhibitor vemurafenib and the excellent tumor response support a pathogenic role for the BRAFV600E mutation in papillary craniopharyngioma. Craniopharyngiomas have not previously been considered as treatable with cytotoxic or targeted agents. BRAF inhibitors may be an effective treatment option as part of the multimodal therapeutic armamentarium for this condition. The successful use of vemurafenib in this patient is a proof-of-concept that justifies further clinical studies and represents a potential paradigm shift in the medical management of patients harbouring a craniopharyngioma.
- 4.Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T (2012) BRAF inhibition in refractory hairy-cell leukemia. Engl J Med 366(2038–203):9Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.